Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

March 14th 2025

All the data on the tumor-agnostic approvals of T-DXd and repotrectinib are featured in this article and it's downloadable PDF visual pages!

Dr Heldermon on a Phase 1/2 Trial Design of Epidiferphane Plus a Taxane in Breast Cancer

March 12th 2025

Coy Heldermon, MD, PhD, discusses a phase 1/2 trial design evaluating pharmacokinetics and safety of epidiferphane given with taxane chemotherapy in breast cancer.

Vepdegestrant Hits PFS End Point in ESR1-Mutated, ER+/HER2– Metastatic Breast Cancer

March 11th 2025

Vepdegestrant improved PFS in ESR1-mutated, ER-positive, HER2-negative metastatic breast cancer, but PFS was not improved in the ITT population.

Alisertib Plus Endocrine Therapy Is Under Evaluation in HR+/HER2-Negative Metastatic Breast Cancer

March 10th 2025

ALISCA-Breast1 is investigating alisertib plus endocrine therapy in HR-positive, HER2-negative recurrent or metastatic breast cancer.

SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer

March 9th 2025

Promising new agents are in development to address the unmet need resulting from resistance to endocrine therapy plus CDK4/6 inhibition in breast cancer.

Atirmociclib Plus Letrozole Demonstrates Preliminary Efficacy and Safety in HR+/HER2-Negative Metastatic Breast Cancer

March 9th 2025

Preliminary data showed atirmociclib plus letrozole yielded antitumor activity in HR-positive/HER2-negative metastatic breast cancer.

Five Under 5: Top Oncology Videos for the Week of 3/2

March 9th 2025

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.

Abemaciclib Delivers Consistent Benefit in High-Risk, Early Breast Cancer Regardless of Dose Reductions

March 8th 2025

Patients with high-risk, early breast cancer receiving adjuvant abemaciclib maintained benefit with the agent regardless of dose modification.

Same-Day Dosing of Eflapegrastim and Chemotherapy Is Safe, Reduces Duration of Severe Neutropenia in Early-Stage Breast Cancer

March 8th 2025

Same-day administration of eflapegrastim and cycle 1 of chemotherapy reduced the mean duration of severe neutropenia in early-stage breast cancer.

Abemaciclib/Fulvestrant Improves PFS Across HR+/HER2– Advanced Breast Cancer Subgroups

March 8th 2025

Benefits were seen with abemaciclib/fulvestrant regardless of metastatic site in HER2-negative advanced breast cancer following prior CDK4/6 inhibition.

Patritumab Deruxtecan Demonstrates Meaningful Activity in HR+/HER2– Advanced Breast Cancer

March 8th 2025

Patritumab deruxtecan elicited responses with acceptable safety in hormone receptor–positive, HER2-negative advanced breast cancer.

Dr Kalinsky on the Potential to Switch CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

March 8th 2025

Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.

Dr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer

March 8th 2025

Sara M. Tolaney, MD, MPH, discusses considerations for the use of adjuvant CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer.

Frontline Palbociclib Combo Improves Outcomes in Real-World HR+/HER2-Negative Breast Cancer Population From Disadvantaged Areas

March 8th 2025

Palbociclib plus an AI prolonged OS and PFS in real-world patients with HR-positive/HER2-negative breast cancer from disadvantaged neighborhoods.

Dr Meattini on Adjuvant Radiotherapy vs Endocrine Therapy in Early Breast Cancer

March 7th 2025

Icro Meattini, MD, discusses the benefits of adjuvant radiation therapy vs endocrine therapy in patients with luminal-like early breast cancer.

PF-07248144 Plus Fulvestrant Is Safe, Active in Pretreated ER+/HER2– Metastatic Breast Cancer

March 7th 2025

PF-07248144 plus fulvestrant was safe and generated responses in pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer.

Updated Data Further Support KEYNOTE-522 Regimen as SOC in High-Risk, Early-Stage TNBC

March 7th 2025

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab provides meaningful OS benefits in high-risk, early-stage TNBC.

Elacestrant Improves PFS Irrespective of ESR1 VAF Level in ER+/HER2-Negative Breast Cancer

March 7th 2025

PFS was extended with elacestrant vs SOC in pretreated, ER-positive, HER2-negative breast cancer, regardless of the level of ESR1 variant allele fraction.

Imulnestrant Plus Abemaciclib Extends PFS Over SOC in ER+/HER2– Advanced Breast Cancer

March 7th 2025

Imlunestrant generated PFS benefit with or without abemaciclib for select patients with ER-positive, HER2-negative advanced breast cancer.

Sacituzumab Govitecan Upholds Efficacy and Safety in Real-World mTNBC Population

March 7th 2025

Treatment with sacituzumab govitecan was effective and tolerable in real-world patients with mTNBC who received the agent in later-line settings.